Hikma Pharmaceuticals PLC Directors report 31 Other matters Principal activity The Directors who held office on 31 December 2006 had the The principal activities of the Group are the development, following interests in the shares and debentures of the Company.
manufacture and marketing of a broad range of generic and in- 1 Preference shares of 1 Ordinary shares of 10 pence licensed pharmaceutical products in solid, semi-solid, liquid and 1 January 31 December 1 January 31 December Director 2006 2006 2006 2006 injectable final dosage forms.
Hikmas operations are conducted through three business segments: Generic Pharmaceuticals, Samih Darwazah 24,999 1,074,506 1,394,506 Branded Pharmaceuticals and Injectable Pharmaceuticals.
Mazen Darwazah 24,999 561,958 561,958 The majority of Hikmas operations are in the MENA region, the United States and Europe.
Michael Ashton 4,566 Ali Al-Husry 1,109,748 1,145,124 The Groups net sales, gross profit, operating profit and are shown by business segment in Note 2 to the consolidated Breffni Byrne 10,000 10,000 financial statements.
Ronald Goode Sir David Rowe-Ham 10,000 10,000 Results and dividends The Groups profit for the year attributable to shareholders in 2006 Total shares: 49,998 2,766,212 3,126,154 was $54.5 million.
The Board is recommending a final dividend 1 The Preference Shares held by the Executive Directors as at 1 January 2006 were of 4.0 cents per share approximately 2.1 pence.
The proposed redeemed by the Company on 9 February 2006. final dividend will be paid on 18 June 2007 to shareholders on the register on 18 May 2007, subject to approval at the No changes in the Directors interests in share capital took place Annual General Meeting.
between 31 December 2006 and the date of this document.
Directors and their interests Creditor payment policy The names of the Directors as at the date of this report, together The companys policy, which is also applied by the Group, is to with details of their roles, backgrounds and abilities, are set out settle terms of payment with suppliers when agreeing the terms in the Directors biographies on pages 24 and 25.
Details of the of each transaction, ensure that suppliers are made aware of independence of Non-Executive Directors are set out in the report the terms of payment and abide by the terms of payment.
on Corporate Governance Principles on pages 26 to 28.
Trade creditors of the Company at 31 December 2006 were equivalent to 74 days purchases, as compared to 77 days at The executive and Non-Executive Directors served the Company 31 December 2005, based on the average daily amount invoiced throughout the year, save for Ronald Goode, who was appointed by suppliers during the year.
as a Non-Executive Director on 12 December 2006.
Having been appointed by the Directors, Dr Goode will retire immediately Charitable and political contributions prior to the next Annual General Meeting and offer himself During the year the Group made charitable donations of for re-election.
$1.0 million, principally to local charities serving the communities Details of Directors share options are provided in the in which the Group operates.
Donations of medicines accounted Remuneration Committee report on pages 33 to 42. for $0.6 million of total donations made.
The Group does not make political donations.
Share capital As at 31 December 2006, the Company had 915 ordinary shareholders and 168,164,207 ordinary shares in issue.
During 2006 the Company issued 1,365,800 ordinary shares pursuant to the exercise of options under the Hikma Pharmaceuticals PLC 2004 Stock Option Plan.
Hikma Pharmaceuticals PLC Directors report 32 Other matters continued Substantial shareholdings Auditors As at 31 December 2006, the Company had been notified Each of the persons who is a Director of the Company at the date pursuant to sections 198 to 208 of the Companies Act 1985 when this report was approved confirms that: Disclosure of interest in shares of the following interests in the so far as the Director is aware, there is no relevant audit ordinary share capital of the Company: information as defined in the Companies Act 1985 of which Percentage the Companys auditors are unaware: and Name of Shareholder Number held the Director has taken all the steps that he or she ought to have Darhold Limited 52,649,972 31.3% taken as a Director to make himself or herself aware of any Capital Research and relevant audit information as defined and to establish that the Management Company 10,223,003 6.1% Companys auditors are aware of that information.
This confirmation is given and should be interpreted in accordance No further notifications were received between 31 December 2006 with the provisions of section 243ZA of the Companies Act 1985. and the date of this document.
Deloitte & Touche LLP have expressed their willingness to continue The Takeover Code Rule 9 in office as auditors and a resolution to reappoint them will be At the Annual General Meeting held on 25 May 2006, a vote proposed at the forthcoming Annual General Meeting.
of the independent shareholders of the Company approved the previous award of 2,520,000 options over ordinary shares to Annual General Meeting Samih Darwazah, Mazen Darwazah, Mohammed Saffouri, The Annual General Meeting of the Company will be held at May Darwazah and Hana Darwazah the Options Holders London Underwriting Centre on Wednesday, 6 June 2007, starting the Whitewash.
Because of the relationship of the Option at 11.00 a. m. The Notice convening the meeting is given in a Holders with Darhold Limited, who at the time of the Annual separate document accompanying this document, and includes General Meeting held 52,649,972 Ordinary Shares representing a commentary on the business of the AGM, and notes to help 31.565% of the issued share capital of the Company at 21 April shareholders exercise their rights at the meeting.
2006, being the latest practicable date prior to the publication Approved by the Board of Directors on 21 March 2007 and signed of the Notice of Annual General Meeting, each of the Option on its behalf Holders together with certain other identified individuals at that date was treated as acting in concert with Darhold Limited for Henry Knowles the purposes of the Takeover Code the Concert Party.
As at Company Secretary 21 April 2006, the Concert Party held, in aggregate, interests in 60,446,652 Ordinary Shares in the capital of Hikma representing 36.239% of the then issued share capital of the Company.
On full exercise of the options the Concert Party would potentially have, in aggregate, interests in 62,966,652 shares in the capital of the Company representing 37.188% of the enlarged issued share capital of the Company, on the basis that no Ordinary Shares were issued other than pursuant to the exercise of such options.
During the period from the Annual General Meeting in 2006 to 21 March 2007, the Option Holders have exercised, in aggregate, options over 364,000 Ordinary Shares in the capital of the Company, of which 44,000 Ordinary Shares were sold immediately upon exercise and 320,000 Ordinary Shares were retained by Options Holders.
Thus, at the date of this document, the Concert Party holds interests in 60,766,652 Ordinary Shares representing 36.135% of the issued share capital of the Company at the date of this document.
